Literature DB >> 16394801

European multi-centre study on coeliac disease and non-Hodgkin lymphoma.

M Luisa Mearin1, Carlo Catassi, Nicole Brousse, Ronald Brand, Pekka Collin, Elisabetta Fabiani, Joachim J Schweizer, Mohamed Abuzakouk, Hania Szajewska, Claes Hallert, Carme Farré Masip, Geoffrey K T Holmes.   

Abstract

INTRODUCTION: Coeliac disease (CD) is associated with an increased risk of non-Hodgkin lymphoma (NHL), but there is little information about whether this is true for clinically silent CD.
OBJECTIVE: To investigate the frequency of CD in two European populations; one with NHL and another derived from the general population.
METHODS: A prospective, multi-centre, case-control study in 10 European countries was conducted between May 1998 and April 2001. A total of 1446 consecutive patients with newly diagnosed NHL aged over 18 years was collected. The control group consisted of a population of 9676 individuals who were screened for CD. The number of patients with a previous diagnosis of CD and those with silent CD detected by screening were determined in the two groups.
RESULTS: The patients with CD had a significantly increased risk of developing NHL [odds ratio (OR) 2.6, 95% confidence interval (CI) 1.4-4.9]. This risk was only present in patients with CD diagnosed clinically before the study (OR 3.3, 95% CI 1.4-7.9), but not in those with silent CD detected by screening (OR 1.3, 95% CI 0.6-2.7).
CONCLUSION: Patients with CD have an increased risk of developing NHL, although this is lower than previously thought. Clinically silent CD is rare in patients with NHL.

Entities:  

Mesh:

Year:  2006        PMID: 16394801     DOI: 10.1097/00042737-200602000-00012

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  25 in total

1.  Increasing incidence of enteropathy-associated T-cell lymphoma in the United States, 1973-2008.

Authors:  Reem Z Sharaiha; Ben Lebwohl; Laura Reimers; Govind Bhagat; Peter H Green; Alfred I Neugut
Journal:  Cancer       Date:  2011-12-13       Impact factor: 6.860

2.  Review.

Authors:  Mohammad Azam; Maire Buckley; Richard J Farrell
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-04

3.  Screening for celiac disease in average-risk and high-risk populations.

Authors:  Saurabh Aggarwal; Benjamin Lebwohl; Peter H R Green
Journal:  Therap Adv Gastroenterol       Date:  2012-01       Impact factor: 4.409

Review 4.  Hematologic manifestations of celiac disease.

Authors:  Thorvardur R Halfdanarson; Mark R Litzow; Joseph A Murray
Journal:  Blood       Date:  2006-09-14       Impact factor: 22.113

5.  Malignancy and mortality in a population-based cohort of patients with coeliac disease or "gluten sensitivity".

Authors:  L A Anderson; S A McMillan; R G P Watson; P Monaghan; A T Gavin; C Fox; L J Murray
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

6.  Recent advances in celiac disease.

Authors:  Hugh James Freeman; Angeli Chopra; Michael Tom Clandinin; Alan Br Thomson
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

7.  Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association.

Authors:  Ying Gao; Sigurdur Y Kristinsson; Lynn R Goldin; Magnus Björkholm; Neil E Caporaso; Ola Landgren
Journal:  Gastroenterology       Date:  2008-09-25       Impact factor: 22.682

8.  Adult celiac disease and its malignant complications.

Authors:  Hugh J Freeman
Journal:  Gut Liver       Date:  2009-12-31       Impact factor: 4.519

9.  Risk of lymphoproliferative malignancy in celiac patients with a family history of lymphoproliferative malignancy.

Authors:  Jonas F Ludvigsson; Benjamin Lebwohl; Alberto Rubio-Tapia; Joseph A Murray; Peter H R Green; Anders Ekbom
Journal:  J Gastroenterol       Date:  2013-02-27       Impact factor: 7.527

10.  Clinical utility of serologic testing for celiac disease in asymptomatic patients: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2011-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.